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on data from a tacrolimus variability study. Cost data were taken primarily from the 
British National Formulary and 2012–13 NHS tariff information and the analysis was 
performed over a 5-year time horizon. Results: The mean cost per patient (includ-
ing tacrolimus, concomitant immunosuppressive medications, dialysis after graft 
failure, and treatment for acute rejection) was GBP 26,958 with Advagraf versus GBP 
30,379 for Prograf over a 5-year period. The total cost saving (GBP 3,421) was driven by 
reduced Advagraf pharmacy costs and lower dialysis costs resulting from the lower 
proportion of patients with high variability in tacrolimus trough concentrations in 
the Advagraf arm, leading to lower risk of graft failure. ConClusions: Converting 
renal transplant recipients from Prograf to Advagraf was associated with lower 
pharmacy and dialysis costs, with the reduction in dialysis costs being driven by the 
lower proportion of Advagraf patients with high tacrolimus trough concentration 
variability and the resultant improvement in graft survival.
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objeCtives: To compare the CKD5 budget requirements of utilizing epoetin alfa 
Hexal vs. darbepoetin alfa in the German health care system. Methods: Chronic 
kidney disease (CKD) is a condition that is prevalent worldwide, and the num-
ber of patients affected continues to increase. ESAs and iron are the mainstays 
of treatment for haemodialysis patients. The purpose of this pharmacoeconomic 
analysis was to evaluate the cost-effectiveness of the short-acting biosimilar ESA 
epoetin-alfa Hexal (EA) 6,000-8,000 IU per week (TIW) vs. long-acting erythropoiesis-
stimulating agent (ESA) darbepoetin alfa (DA) 30-40 mcg weekly (QW), for treating 
chronic haemodialysis patients. A budget impact model was constructed employ-
ing a payer perspective, per patient with 5 year time horizon. The treatment period 
considered was based on 52 weeks and was aligned with real world clinical experi-
ence data from germany1. Model inputs included: medical treatment, outcomes, 
and health care service utilization from published clinical studies2and summary 
of product characteristics recommendation. Effectiveness of therapeutic alterna-
tives was determined by comparing haemoglobin maintenance rates. Costs pre-
sented reflect 2013 prices. The analysis was performed from the perspective of the 
German health care system. Results: The average expected pharmaceutical costs 
per patient were € 3791 to € 5002 for DA QW (30-40mcg weekly) versus € 2690 to € 3520 
for EA TIW (6,000-8,000IU weekly). Cost-savings associated with utilizing EA TIW 
was 41-42% for comparable DA doses. Previous German research has demonstrated 
that ESA consumption of patients on chronic haemodialysis based on DDD is similar 
for biosimilar and originator ESAs1. ConClusions: In the treatment of chronic 
haemodialysis patients in Germany, epoetin alfa Hexal is projected to provide sub-
stantial savings for the health care system when compared to darbepoetin alfa. 
German stakeholders could consider the extent that darbepoetin alfa is utilized in 
haemodialysis patients. [1] Horbrand et al. Eur J Clin Pharmacol 10/2012. [2] Horl et 
al. Clin. Nephrology 1/2012.
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objeCtives: AKI is common in the ICU and often necessitates the provision of 
renal replacement therapy (RRT). Two main modalities exist: continuous (CRRT) 
or intermittent (IRRT) therapy. Neither modality has been found superior in terms 
of survival. However, dialysis dependence among survivors remains a significant 
medical and economic issue. A recent meta-analysis showed initial IRRT might be 
associated with higher rates of dialysis dependence than initial CRRT. We performed 
a preliminary cost-utility analysis comparing both modalities based on these recent 
data. Methods: We assumed a pool of patients who would potentially be eligible 
for either modality and modeled LYG, QALYs gains and costs comparing initial CRRT 
vs. initial IRRT, all else being the same. Using the US perspective, we designed a 
1-year Markov model with daily cycle and 2 health states (dialysis independence/
dependence). Survival for both modalities was fitted from published estimates 
(Weibull regression). The proportion of dialysis independent survivors was fitted 
from published estimates for CRRT (Weibull regression). IRRT dialysis independence 
estimates were obtained by applying the meta-analysis risk-ratio to the fitted CRRT 
estimates. Sensitivity analysis was conducted on the daily implementation cost 
difference between CRRT and IRRT (from $250 to $1,000; basecase: $500) and the 
risk-ratio for dialysis dependence for IRRT as compared to CRRT (from 1.20 to 3.00; 
basecase: 1.99). Results: The QALYs gain was slightly better for CRRT as compared 
to IRRT (0.301 vs. 0.292 respectively). Despite higher hospitalization costs for CRRT 
($86,397 vs. $83,309 for IRRT), the one-year cumulative total cost including the cost 
of dialysis dependence was similar between the two modalities ($94,286 for CRRT 
vs. $94,118 for IRRT). In the basecase analysis, the ICER of CRRT vs. IRRT was $17,562/
QALY. ConClusions: Initial CRRT may actually be cost-effective as compared to 
initial IRRT by reducing the rate of dialysis dependence among AKI survivors.
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objeCtives: To understand the trends in rate and cost of hospitalizations due to 
Chronic Kidney Disease (CKD) in the U.S. Methods: We analyzed the last five years 
Urinary/KidnEy disordErs – cost studies
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objeCtives: The increasing prevalence of end-stage kidney disease in the UK 
has resulted in a heavy economic burden. The National Institute of Health and 
Care Excellence reported that patients receiving dialysis at home have better 
health outcomes and lower health care resource use. This study aims to assess 
the financial impact of increasing the use of home-based dialyses vs. UK current 
practice. Methods: A Markov model was constructed to estimate the financial 
impact of different dialysis scenarios from the UK payer perspective. We modelled 
prevalent and incident dialysis patient population over 5 years. The current UK 
dialysis modality distribution of 15% prevalent and 20% incident peritoneal dialysis 
(PD), 82% prevalent and 79% incident in-centre haemodialysis (ICHD), 3% prevalent 
and 1% incident conventional home HD (HHD), and 0% high dose HHD was com-
pared to 3 scenarios: 1) Increase high dose HHD to 10% among prevalent patients; 
2) Increase high dose HHD to 10% and PD to 20% among prevalent patients and 
increase PD to 25% among incident patients; 3) Increase high dose HHD to 10% 
and PD to 25% among prevalent patients and increase PD to 30% among incident 
patients. In each scenario, the proportion of patients on ICHD changes accord-
ingly, while conventional HHD is kept constant. Model inputs were from published 
sources. Results: The base case results show that all 3 scenarios result in lower 
costs versus current UK practice. A prevalent population size of 22,654 patients was 
modelled, accounting for an annual incident population size of 5,393 in England. 
Scenario 1 saves £25 million (£559 per patient). Scenario 2 saves £67 million (£1,526 
per patient). Scenario 3 saves £110 million (£2,493 per patient). Sensitivity analyses 
demonstrate consistent results. ConClusions: Under the current UK national 
tariff, increasing the proportion of patients on home-based dialyses is associated 
with lower total health care costs.
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objeCtives: Advagraf® is a once-daily prolonged-release formulation of tacrolimus 
with proven non-inferiority to Prograf®, a twice-daily immediate-release formula-
tion of tacrolimus, in biopsy-proven acute rejection in renal transplant recipients. 
Advagraf is associated with improved adherence compared with Prograf, which may 
ultimately improve long-term outcomes. The present study assessed the budget 
impact of switching patients from Prograf to Advagraf in the UK. Methods: A 
budget impact model was constructed based on published data on acute rejection, 
graft failure and mortality in the UK setting. Patients were assumed to convert from 
Prograf to Advagraf on a 1:1 mg:mg basis. In a study comparing the adherence rates 
between once-daily versus twice-daily formulations of tacrolimus, the proportion 
of patients taking the prescribed number of daily doses was 88.2% in Advagraf 
patients and 78.8% in Prograf patients. The model applied a relative risk of graft 
failure of 3.47 to non-adherent patients based on data from a 2004 meta-analysis. 
Cost data were taken from the British National Formulary and 2012–13 NHS tariff 
information. The analysis was performed over a 5-year time horizon and future costs 
were not discounted, in line with International Society for Pharmacoeconomic and 
Outcomes Research guidelines. Results: Over a 5-year time horizon, the mean cost 
per patient (including tacrolimus, concomitant immunosuppressive medications, 
dialysis after graft failure, and treatment for acute rejection) was GBP 29,290 for 
Advagraf versus GBP 33,032 for Prograf. The total cost saving of GBP 3,742 was driven 
by reduced Advagraf pharmacy costs and lower dialysis costs arising from the lower 
risk of graft failure in the larger proportion of adherent patients in the Advagraf 
arm. ConClusions: Conversion of renal transplant recipients from Prograf to 
Advagraf was associated with lower pharmacy and dialysis costs, with the reduc-
tion in dialysis costs being driven by improved adherence to Advagraf regimen and 
the consequent improvement in graft survival.
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objeCtives: Randomized controlled trials have shown that Advagraf®, a once-daily 
prolonged-release tacrolimus formulation, is non-inferior to Prograf®, a twice-daily 
immediate-release tacrolimus formulation, in terms of biopsy-proven acute rejec-
tion in renal transplant recipients. However, relative to Prograf, Advagraf exhibits 
reduced variability in tacrolimus trough concentration, which has been associated 
with reduced graft failure. Based on these data, the present study evaluated the 
cost of switching UK renal transplant patients from Prograf to Advagraf. Methods: 
UK-specific data on acute rejection, graft failure and mortality were used to 
construct a budget impact model to assess the costs of switching from Prograf 
to Advagraf on a 1:1 mg:mg basis. The model assumed that 3.1% of patients on 
Advagraf had high tacrolimus trough concentration variability compared with 17.4% 
on Prograf, based on a study comparing Advagraf and Prograf pharmacokinetics. The 
model applied a relative risk of graft failure of 2.38 to high variability patients based 
